Marcus C S, Stabin M G, Watson E E, Kuperus J H
J Nucl Med. 1985 Sep;26(9):1091-3.
Indium-114m and 114In appear as contaminants in commercial preparations of [111In]oxine at a level of about 0.05% at time of calibration (TOC). The contribution of these contaminants to the radiation absorbed dose from [111In]oxine leukocyte, platelet, and erythrocyte imaging procedures has been evaluated. When the absorbed dose from these contaminants is expressed as a percent of the 111In dose to the same organ from a given procedure, the contaminants contribute an additional 0.16 to 12% of the 111In dose, and in one case, that of the spleen from [111In]oxine labeled erythrocytes, they contribute an additional 33%. Commercial samples of aqueous-based [111In]oxine contain levels of 114mIn/114In sufficient to result in a mild to moderate increase in the absorbed radiation dose to the patient. Strict quality control procedures must be maintained by suppliers to prevent higher contamination levels. It is advisable to avoid using 111In products of this nature later than about 3 days after the time of calibration.
铟 - 114m和114In在校准(TOC)时作为[111In]氧嗪酸盐商业制剂中的污染物出现,含量约为0.05%。已评估了这些污染物对[111In]氧嗪酸盐白细胞、血小板和红细胞成像程序中辐射吸收剂量的贡献。当这些污染物的吸收剂量表示为给定程序中同一器官接受的111In剂量的百分比时,污染物对111In剂量的额外贡献为0.16%至12%,在一种情况下,即[111In]氧嗪酸盐标记红细胞对脾脏的剂量贡献中,它们额外贡献了33%。水基[111In]氧嗪酸盐的商业样品中114mIn/114In的含量足以导致患者吸收辐射剂量出现轻度至中度增加。供应商必须维持严格的质量控制程序,以防止更高的污染水平。建议避免使用校准时间超过约3天后的此类111In产品。